Skip to main content
. 2017 Jun 9;14(2):917–930. doi: 10.3892/etm.2017.4576

Figure 6.

Figure 6.

Effects of atorvastatin treatment on tTG, p-Smad3, HIF-1a, VEGF, and TGF-β1 protein expression. Mice were treated with atorvastatin or Dex and challenged with OVA (nebulized 2.5% solution 30 min/day, 3 days/week for 6 weeks). tTG, p-Smad3, HIF-1α, VEGF and TGF-β1 protein were measured by western blot analysis. (A) Representative western blots showing the protein expression levels of tTG, p-Smad3, HIF-1α, VEGF and TGF-β1 in the four groups of mice. Lanes: a, control group; b, model group; c, treatment group; d, Dex group. (B) Densitometrically quantified protein levels of tTG, p-Smad3, HIF-1α, VEGF and TGF-β1 in the four groups. Values are expressed as the mean ± standard deviation of one experiment consisting of three replicates. The experiments were performed in triplicates. **P<0.05, vs. control group; #P<0.05 vs. model group. Dex, dexamethasone; VEGF, vascular endothelial growth factor; TGF-β, transforming growth factor β; HIF, hypoxia-inducible factor; tTG, tissue transglutaminase; p-Smad3, phosphorylated Smad3.